The U.S. Court of Appeals for the Third Circuit in a split decision today affirmed a district court ruling granting summary judgment to the U.S. government that the imposition of a Medicare Drug Price Negotiation Program via the Inflation Reduction Act (IRA) does not violate Bristol Myers Squibb (BMS) and Janssen Pharmaceuticals’ constitutional rights. Judge Hardiman dissented.

Full Article Available Here